However, among those patients treated with clopidogrel, the patients carrying at least one CYP2C19 reduced-function allele were at significantly higher risk for the primary outcome of IS, TIA, MI, or death than noncarriers (22.7% [29/128] vs. 11.5% [18/156]; hazard ratio for carriers, 3.02; 95% confidence interval (CI), 1.23 to 8.74; P = 0.012) (Figure 1 and Table 3). The gene discussed is CYP2C19; the disease is transient ischemic attack.